Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 ,inter alia, to consider and approve 1. Unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has informed BSE that its Board of Directors will meet on Friday, February 13, 2026, at the registered office in Hyderabad. The agenda includes approving the unaudited financial results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report for the same period. The intimation was filed under SEBI LODR Regulation 29(1)(a) and signed by Executive Director Dhananjaya Alli. No actual financial numbers have been disclosed in this filing — it is purely a pre-meeting notice.
This is a routine regulatory intimation with no immediate impact on the stock. Investors should watch for the actual Q3 FY26 results announcement on or after February 13, 2026, for revenue, profit, and margin trends.